These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16815856)

  • 21. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V; Castro C; Campistol JM
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report.
    Lasmar EP; Coelho LG; Lasmar MF; Lasmar LF; Lima PV; Nogueira AF
    Transplant Proc; 2009 Apr; 41(3):959-61. PubMed ID: 19376398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H; Hetzer R
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.
    Carreño CA; Gadea M
    Transplant Proc; 2007 Apr; 39(3):594-5. PubMed ID: 17445552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
    Rehm B; Keller F; Mayer J; Stracke S
    Transplant Proc; 2006 Apr; 38(3):711-3. PubMed ID: 16647451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
    Audard V
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
    Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
    Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V; Gutierrez C; Cabello M; Burgos D; Sola E; Gonzalez-Molina M
    Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
    Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.